A Phase 3 interventional study of secukinumab and Placebo in Lupus Nephritis, sponsored by Novartis Pharmaceuticals. Terminated at 105 sites in 34 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lupus Nephritis by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Lupus Nephritis · Novartis.
Among the 10 studies in Lupus Nephritis by Novartis, this one is the only one that started in 2020, is one of 4 in phase 3, and was the 3rd registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →1 of the 10 studies in Lupus Nephritis by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, China and 15 more countries
Ages 18–100
By country, each count listing its studies:
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2020.
This study's enrollment of 275 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 81 across the 9 interventional studies, 69 across the 1 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Lupus Nephritis by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Lupus Nephritis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) also receiving background standard of care therapy (SoC).
The study consisted of the following parts:
A total of 275 subjects were enrolled and were randomized to secukinumab 300 mg (n = 137) or placebo (n = 138) until study termination. Recruitment in this study was stopped on 26-May-2023. The CAIN457Q12301 study was terminated early by Novartis due to futile results from interim analysis 1 (IA1). There was no safety related reasons for early termination or concerns for the subjects in the study. The decision was made to terminate both the core and the related extension study in view of treatment futility of the core study.
Key inclusion criteria:
Confirmed diagnosis of:
Active lupus nephritis, as defined by meeting the 4 following criteria:
Key Exclusion criteria:
Any of the following abnormal laboratory values on Screening evaluations as reported by Central Laboratory:
In case local regulations deviated from the contraception methods listed above, local regulations applied and were described in the informed consent form (ICF).
If stricter female or male contraception requirements were specified in the country-specific label for induction and maintenance standard of care medications, they had to be followed.
Note: Women were considered and not of childbearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks prior to enrollment. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow-up hormone level assessment was she considered not of childbearing potential.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blinded, weekly, subcutaneous (s.c.) secukinumab 300 mg loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.
Drug: secukinumab
A blinded, weekly, subcutaneous (s.c.) matching placebo loading regimen was administered for the first 4 weeks followed by a monthly maintenance dose in all randomized subjects thereafter.
Drug: Placebo
STUDY DRUG
Also known as: AIN457
Placebo
Percentage of Participants Achieving Complete Renal Response (CRR) at Week 52
Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg * No treatment discontinuation before Week 52 * The subject did not receive more than 10 mg/day prednisone or equivalent for \>= 3 consecutive days or for \>= 7 days in total during Week 44 through Week 52. Non-responder imputation (NRI) was used for participants who did not have the required data to compute responses at Week 52 or who had discontinued study treatment before Week 52. A logistic regression model was used for the analysis of this endpoint.
Time frame: Baseline, Week 52
Change From Baseline in 24-hour Urine Protein-to Creatinine Ratio (UPCR)
Urine Protein-to-Creatinine Ratio (UPCR) was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected (24-hour urine collection sample).
Time frame: Baseline, Week 52
Percentage of Participants Achieving Partial Renal Response (PRR) at Week 52
Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline
Time frame: Baseline, Week 52
Average Daily Dose of Oral Corticosteroids
Average daily dose of oral corticosteroids doses was used to assess efficacy of secukinumab compared to placebo in the averaged daily dose of oral corticosteroids administered between Week 16 and Week 52.
Time frame: Week 16 to Week 52
Percentage of Participants Achieving Partial Renal Response (PRR) at Week 24
Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline
Time frame: Baseline, Week 24
Incidence Rate of Participants Achieving Complete Renal Response (CRR) up to Week 52
Time to achieve Complete Renal Response (CRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve CRR were censored at the date of their last non-missing CRR result (including participants who completed week 52 without achieving CRR). * Subjects at risk = Subjects who did not achieve CRR and were not censored before or at the start of the specified interval. Participants had an event when achieving CRR. * Incidence rate (%) = (number of subjects with event/number of subjects at risk) x 100.
Time frame: Baseline to Week 52
Incidence Rate of Participants Achieving Partial Renal Response (PRR) up to Week 52
Time to achieve Partial Renal Response (PRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve PRR were censored at the date of their last non-missing PRR result (including participants who completed week 52 without achieving PRR). Participants had event when achieving PRR. * Subjects at risk = Subjects who did not achieve PRR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.
Time frame: Baseline to Week 52
Time to Achieve First Morning Void Urine Protein-to-Creatinine Ratio (UPCR) <= 0.5 mg/mg up to Week 52
Time to achieve first morning void Urine Protein-to-Creatinine Ratio (UPCR) \<= 0.5 mg/mg up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve UCPR were censored at the date of their last non-missing UCPR result (including participants who completed week 52 without achieving UCPR). Participants had event when achieving UCPR. * Subjects at risk = Subjects who did not achieve UCPR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.
Time frame: Baseline to Week 52
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Mean Change From Baseline up to Week 52
The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past week. The purpose of the FACIT-Fatigue in this study was to assess the impact of fatigue on subjects with lupus nephritis (LN). The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much) based on their experience of fatigue during the past 2 weeks. The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. FACIT-Fatigue scale score range from 0 to 52, where higher scores represent less fatigue.
Time frame: Baseline, Week 12, Week 24, Week 36, Week 52
Short Form Health Survey (SF-36) Version 2 (Acute Form) Mean Change From Baseline in Physical Component Score (PCS) up to Week 52
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). In this trial, SF-36-PCS responder (improvement of \>= 2.5 points) were evaluated. Responses to items allow for direct calculation of scale scores, while the physical component summary (PCS) scores are computed from weighted scale scores. For all scales and summary measures, higher scores indicate better health outcomes (PCS scores range 0 to 100).
Time frame: Baseline, Week 12, Week 24, Week 36, Week 52
Lupus Quality of Life (LupusQoL) Physical Health Score Mean Change From Baseline up to Week 52
The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of subjects with SLE within 8 domains (i.e., physical health (8 items), emotional health (6 items), body image (5 items), pain (3 items), planning (3 items), fatigue (4 items), intimate relationships (2 items), and burden to others (3 items)). Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). Each domain of the LupusQoL was scored separately. Transformed scores range from 0 (worst HRQoL) to 100 (best HRQoL).
Time frame: Baseline, Week 12, Week 24, Week 36, Week 52
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs)
The distribution of adverse events was done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.
Time frame: From first dose of study treatment up to approximately 2 years
Percentage of Participants With Complete Renal Response (CRR) at Week 104 Within Those Who Had Achieved CRR at Week 52 in the Secukinumab Group
The percentage of participants with maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated
Time frame: Week 52 to Week 104
Percentage of Participants With Improved or Maintained Response (PRR or CRR) at Week 104 in Those Who Had Achieved at Least PRR at Week 52 in the Secukinumab Group
The percentage of participants with improved or maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated
Time frame: Week 52 to Week 104
This study was conducted in 106 centers in 34 countries worldwide.
| Milestone | Secukinumab 300 mg | Placebo |
|---|---|---|
| Started | 137 | 138 |
| Full analysis set 2 | 91 | 91 |
| Pharmacokinetic set | 136 | 0 |
| Completed | 23 | 23 |
| Not completed | 114 | 115 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Study terminated by sponsor | 95 | 97 |
| Withdrew: Subject decision | 11 | 4 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Withdrawal of informed consent | 1 | 3 |
Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg * No treatment discontinuation before Week 52 * The subject did not receive more than 10 mg/day prednisone or equivalent for \>= 3 consecutive days or for \>= 7 days in total during Week 44 through Week 52. Non-responder imputation (NRI) was used for participants who did not have the required data to compute responses at Week 52 or who had discontinued study treatment before Week 52. A logistic regression model was used for the analysis of this endpoint.
| Percentage of participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Complete Renal Response (CRR) at Week 52 | 25.9 (16.8 to 34.9) | 38.6 (28.5 to 48.7) |
Urine Protein-to-Creatinine Ratio (UPCR) was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected (24-hour urine collection sample).
| mg/mg | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change From Baseline in 24-hour Urine Protein-to Creatinine Ratio (UPCR) | -2.204 ± 3.5162 | -2.741 ± 5.9448 |
Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline
| Percentage of participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Partial Renal Response (PRR) at Week 52 | 56.2 (44.1 to 67.8) | 63.9 (51.7 to 74.9) |
Average daily dose of oral corticosteroids doses was used to assess efficacy of secukinumab compared to placebo in the averaged daily dose of oral corticosteroids administered between Week 16 and Week 52.
| mg/day | Secukinumab 300 mg | Placebo |
|---|---|---|
| Average Daily Dose of Oral Corticosteroids | 8.1243 ± 6.38329 | 7.4791 ± 5.61958 |
Partial Renal Response (PRR) is a composite endpoint defined as: * \>= 50% reduction in 24-hour Urine-to-Protein Creatinine Ratio (UPCR) to sub-nephrotic levels (=\< 3 mg/mg) and * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of Baseline
| Percentage of participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Percentage of Participants Achieving Partial Renal Response (PRR) at Week 24 | 52.8 (42.9 to 62.5) | 43.6 (34.2 to 53.4) |
Time to achieve Complete Renal Response (CRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve CRR were censored at the date of their last non-missing CRR result (including participants who completed week 52 without achieving CRR). * Subjects at risk = Subjects who did not achieve CRR and were not censored before or at the start of the specified interval. Participants had an event when achieving CRR. * Incidence rate (%) = (number of subjects with event/number of subjects at risk) x 100.
| Percentage of participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| 1 to 28 days | 0.0 | 0.8 |
| 29 to 56 days | 0.0 | 0.0 |
| 57 to 84 days | 3.1 | 5.4 |
| 85 to 112 days | 11.7 | 16.8 |
| 113 to 140 days | 0.0 | 2.2 |
| 141 to 168 days | 0.0 | 3.4 |
| 169 to 196 days | 20.4 | 20.0 |
| 197 to 224 days | 1.4 | 0.0 |
| 225 to 252 days | 0.0 | 0.0 |
| 253 to 280 days | 14.8 | 3.6 |
| 281 to 308 days | 0.0 | 2.1 |
| 309 to 336 days | 0.0 | 0.0 |
| 337 to 364 days | 2.3 | 7.3 |
Time to achieve Partial Renal Response (PRR) up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve PRR were censored at the date of their last non-missing PRR result (including participants who completed week 52 without achieving PRR). Participants had event when achieving PRR. * Subjects at risk = Subjects who did not achieve PRR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.
| Percentage of participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| 1 to 28 days | 0.0 | 0.8 |
| 29 to 56 days | 0.0 | 0.0 |
| 57 to 84 days | 7.0 | 5.4 |
| 85 to 112 days | 27.8 | 30.5 |
| 113 to 140 days | 1.3 | 2.6 |
| 141 to 168 days | 0.0 | 4.1 |
| 169 to 196 days | 32.4 | 14.9 |
| 197 to 224 days | 2.4 | 0.0 |
| 225 to 252 days | 2.6 | 0.0 |
| 253 to 280 days | 11.8 | 16.3 |
| 281 to 308 days | 4.0 | 2.9 |
| 309 to 336 days | 0.0 | 0.0 |
| 337 to 364 days | 0.0 | 6.5 |
Time to achieve first morning void Urine Protein-to-Creatinine Ratio (UPCR) \<= 0.5 mg/mg up to week 52 was evaluated by 4-week interval by using Kaplan-Meier estimates. Participants who did not achieve UCPR were censored at the date of their last non-missing UCPR result (including participants who completed week 52 without achieving UCPR). Participants had event when achieving UCPR. * Subjects at risk = Subjects who did not achieve UCPR and were not censored before or at the start of the specified interval. * Incidence rate (%) = (number of subjects with event/ number of subjects at risk) x 100.
| Percentage of participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| 1 to 28 days | 19.3 | 21.3 |
| 29 to 56 days | 2.8 | 5.6 |
| 57 to 84 days | 8.7 | 7.0 |
| 85 to 112 days | 11.8 | 9.7 |
| 113 to 140 days | 7.6 | 7.4 |
| 141 to 168 days | 9.9 | 6.9 |
| 169 to 196 days | 9.7 | 3.2 |
| 197 to 224 days | 7.5 | 11.9 |
| 225 to 252 days | 4.2 | 6.0 |
| 253 to 280 days | 4.4 | 0.0 |
| 281 to 308 days | 12.2 | 4.5 |
| 309 to 336 days | 0.0 | 5.1 |
| 337 to 364 days | 3.1 | 2.9 |
The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past week. The purpose of the FACIT-Fatigue in this study was to assess the impact of fatigue on subjects with lupus nephritis (LN). The level of fatigue was measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much) based on their experience of fatigue during the past 2 weeks. The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. FACIT-Fatigue scale score range from 0 to 52, where higher scores represent less fatigue.
| Unit on a scale | Secukinumab 300 mg | Placebo |
|---|---|---|
| Week 12 | -2.8 ± 8.47 | -1.9 ± 8.46 |
| Week 24 | -1.4 ± 9.66 | -2.0 ± 8.93 |
| Week 36 | -2.6 ± 9.21 | -2.1 ± 9.67 |
| Week 52 | -2.0 ± 10.18 | -2.0 ± 9.51 |
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). In this trial, SF-36-PCS responder (improvement of \>= 2.5 points) were evaluated. Responses to items allow for direct calculation of scale scores, while the physical component summary (PCS) scores are computed from weighted scale scores. For all scales and summary measures, higher scores indicate better health outcomes (PCS scores range 0 to 100).
| Unit on a scale | Secukinumab 300 mg | Placebo |
|---|---|---|
| Week 12 | 2.306 ± 6.4306 | 2.210 ± 6.8760 |
| Week 24 | 2.873 ± 6.4502 | 1.687 ± 6.5346 |
| Week 36 | 2.910 ± 6.8234 | 3.152 ± 7.0623 |
| Week 52 | 3.410 ± 7.7123 | 2.707 ± 6.8887 |
The LupusQoL is a disease-specific, 34-item, self-report questionnaire designed to measure the health-related quality of life (HRQoL) of subjects with SLE within 8 domains (i.e., physical health (8 items), emotional health (6 items), body image (5 items), pain (3 items), planning (3 items), fatigue (4 items), intimate relationships (2 items), and burden to others (3 items)). Responses are based on a 5-point Likert scale where 0 (all of the time) to 4 (never). Each domain of the LupusQoL was scored separately. Transformed scores range from 0 (worst HRQoL) to 100 (best HRQoL).
| Unit on a scale | Secukinumab 300 mg | Placebo |
|---|---|---|
| Week 12 | 5.32 ± 16.031 | 6.18 ± 19.248 |
| Week 24 | 4.84 ± 18.184 | 5.55 ± 20.485 |
| Week 36 | 5.59 ± 20.684 | 7.89 ± 23.112 |
| Week 52 | 7.62 ± 23.275 | 8.55 ± 20.589 |
The distribution of adverse events was done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Deaths | 1 | 1 |
| Serious Adverse Event (TESAEs) | 30 | 39 |
| Treatment Emergent Adverse Event (TEAEs) | 120 | 123 |
| TESAEs leading to study medication discontinuation | 8 | 10 |
The percentage of participants with maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated
| Participants | Secukinumab 300 mg |
|---|---|
| Achieve CRR | 5 |
| Not Achieve CRR | 1 |
The percentage of participants with improved or maintained renal response (CRR) at Week 104 in the secukinumab group was evaluated
| Participants | Secukinumab 300 mg |
|---|---|
| Achieve PRR or CRR | 11 |
| Not achieve PRR or CRR | 1 |
Collected over On-treatment adverse events and deaths were reported from first dose of study treatment to 84 days after last dose of study medication, assessed up to approximately 2 years.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg | 1/137 (0.7%) | 30/137 (21.9%) | 111/137 (81%) |
| Placebo | 1/138 (0.7%) | 39/138 (28.3%) | 116/138 (84.1%) |
| Event | Secukinumab 300 mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 5/137 | 3/138 |
| Lupus nephritisRenal and urinary disorders | 4/137 | 5/138 |
| COVID-19Infections and infestations | 3/137 | 4/138 |
| Acute kidney injuryRenal and urinary disorders | 1/137 | 4/138 |
| CataractEye disorders | 2/137 | 1/138 |
| Pyelonephritis acuteInfections and infestations | 2/137 | 1/138 |
| Urinary tract infectionInfections and infestations | 0/137 | 2/138 |
| AnaemiaBlood and lymphatic system disorders | 1/137 | 0/138 |
| PancytopeniaBlood and lymphatic system disorders | 1/137 | 0/138 |
| DyspepsiaGastrointestinal disorders | 1/137 | 1/138 |
| Event | Secukinumab 300 mg | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 19/137 | 30/138 |
| Upper respiratory tract infectionInfections and infestations | 19/137 | 26/138 |
| COVID-19Infections and infestations | 25/137 | 22/138 |
| DiarrhoeaGastrointestinal disorders | 23/137 | 21/138 |
| HeadacheNervous system disorders | 21/137 | 14/138 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/137 | 19/138 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/137 | 14/138 |
| AnaemiaBlood and lymphatic system disorders | 12/137 | 13/138 |
| NauseaGastrointestinal disorders | 11/137 | 5/138 |
| NasopharyngitisInfections and infestations | 11/137 | 11/138 |
| Age, Continuous(Years) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Mean | 34.1 ± 10.84 | 33.2 ± 11.28 | 33.6 ± 11.05 |
| Age, Customized(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| < 30 years | 55 | 64 | 119 |
| >= 30 years | 82 | 74 | 156 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Female | 116 | 124 | 240 |
| Male | 21 | 14 | 35 |
| Race (NIH/OMB)(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 21 | 21 | 42 |
| Asian | 67 | 56 | 123 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 9 | 15 |
| White | 42 | 52 | 94 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 105 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2020 to primary completion in Sep 2023, 38 months.
Results were first posted in Oct 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab